Personal stories

This disease is highly treatable if caught early—but in its earliest stages, prostate cancer often has no symptoms, allowing it to develop without detection. Learn more about this common cancer and how Johnson & Johnson is innovating across both early-stage and advanced disease.

Jordan Schecter, M.D., leader of Johnson & Johnson’s end-to-end development strategy for multiple myeloma, shares insight on the evolving treatment landscape of this rare blood cancer.

Across New Jersey, more than one million people face food insecurity while millions of prepared meals go to waste each year. Through partnerships like the Meal Recovery Coalition, Johnson & Johnson is helping recover surplus food, strengthen local food systems and expand access to nutritious meals in communities where needs are greatest.

By combining deep understanding of technology and science with our people’s determination, Johnson & Johnson is powering the future of human health.

Inflammatory bowel disease (IBD) is often described as an “invisible illness” due to symptoms that aren’t always apparent to others. But for the millions living with the disease, the impact goes beyond physical symptoms. Learn how Johnson & Johnson is helping create a patient community for those dealing with the heavy psychological toll of IBD.

Warm autoimmune hemolytic anemia (wAIHA) causes fatigue so profound, it can limit the lives of people who have the condition. Learn more about this rare disease and Johnson & Johnson’s clinical research and ongoing commitment to patients.

For 25 years, Johnson & Johnson has pursued innovative blood cancer treatments. Scientist Kodandaram “Ram” Pillarisetti has helped shape that pursuit, from discovering a target that led to an approved bispecific therapy to research exploring a next-generation trispecific antibody approach.